Elite Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Elite Pharmaceuticals, Inc.
Medtech Insight's Deal-Making column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics and Medical Devices – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in July 2022. Data provided by Biomedtracker.
The pharmaceutical company has made a bold play to expand its presence in the device space, giving iSTAR upfront cash in a deal that grants it the right to buy iSTAR for almost half a billion dollars.
China reports flu outbreaks as COVID-19 cases decline, suggesting that population immunity may have been affected by the country's strict "COVID Zero" policies. The cost and availability of flu vaccines in the country are other policy factors playing into the situation.
With India’s first and the world’s third mRNA vaccine, Gennova plans to provide access to its COVID-19 vaccine to those deprived of doses from Pfizer and Moderna. HDT Bio Corp’s suit in the US is not seen impacting marketing plans in India, COO tells Scrip
- Generic Drugs
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Elite Laboratories, Inc.